Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals

Virology

Volumn 427, Issue 2, 2012, Pages 198-207

  Gorny, Miroslaw K ^a   Pan, Ruimin ^a   Williams, Constance ^a   Wang, Xiao Hong ^b   Volsky, Barbara ^a   O'Neal, Timothy ^a   Spurrier, Brett ^a   Sampson, Jared M ^a   Li, Liuzhe ^a   Seaman, Michael S ^c   Kong, Xiang Peng ^a   Zolla Pazner, Susan ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Envelope proteins; Glycosylation; HIV neutralizing antibodies; HIV 1; Human monoclonal antibodies; V2 domain

Indexed keywords

ALPHA4BETA7 INTEGRIN; EPITOPE; GLYCOPROTEIN GP 120; INTEGRIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY V2; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN RECOGNITION; ANTIGEN STRUCTURE; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; CROSS REACTION; CRYSTAL STRUCTURE; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOCHEMISTRY; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOGLOBULIN LIGHT CHAIN GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN TARGETING; VIRUS ATTACHMENT; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84862828547     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.02.003     Document Type: Article

References (64)

1. Abagyan R., Totrov M., Kuznetsov D. ICM-a new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. J. Comput. Chem. 1994, 15(5):488-506.
2. Adams P.D., Grosse-Kunstleve R.W., Hung L.W., Ioerger T.R., McCoy A.J., Moriarty N.W., Read R.J., Sacchettini J.C., Sauter N.K., Terwilliger T.C. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 2002, 58(Pt 11):1948-1954.
3. Arthos J., Cicala C., Martinelli E., Macleod K., Van Ryk D., Wei D., Xiao Z., Veenstra T.D., Conrad T.P., Lempicki R.A., McLaughlin S., Pascuccio M., Gopaul R., McNally J., Cruz C.C., Censoplano N., Chung E., Reitano K.N., Kottilil S., Goode D.J., Fauci A.S. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 2008, 9(3):301-309.
4. Burke V., Williams C., Sukumaran M., Kim S.-S., Li H., Wang X.-H., Gorny M.K., Zolla-Pazner S., Kong X.-P. Structural basis of the cross-reactivity of genetically related human anti-HIV-1 monoclonal antibodies: implications for design of V3-based immunogens. Structure 2009, 17(11):1538-1546.
5. Changela A., Wu X., Yang Y., Zhang B., Zhu J., O'Dell S., Pancera M., Gorny M.K., Phogat S.K., Robinson J.E., Stamatatos L., Zolla-Pazner S., Mascola J.R., Kwong P.D. Crystal structure of human antibody 2909 reveals conserved features of quaternary-specific antibodies that potentially neutralize HIV-1. J. Virol. 2011, 85(6):2524-2535.
6. Corti D., Langedijk J.P., Hinz A., Seaman M.S., Vanzetta F., Fernandez-Rodriguez B.M., Silacci C., Pinna D., Jarrossay D., Balla-Jhagjhoorsingh S., Willems B., Zekveld M.J., Dreja H., O'Sullivan E., Pade C., Orkin C., Jeffs S.A., Montefiori D.C., Davis D., Weissenhorn W., McKnight A., Heeney J.L., Sallusto F., Sattentau Q.J., Weiss R.A., Lanzavecchia A. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010, 5(1):e8805.
7. DeLano W.L. The PyMOL User's Manual 2002, DeLano Scientific, Palo Alto.
8. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., Goudsmit J., Wilson I.A. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324(5924):246-251.
9. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 2004, 60(Pt 12):2126-2132.
10. Gigler A., Dorsch S., Hemauer A., Williams C., Kim S., Young N.S., Zolla-Pazner S., Wolf H., Gorny M.K., Modrow S. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J. Virol. 1999, 73(3):1974-1979.
11. Gorny M.K., Xu J.-Y., Gianakakos V., Karwowska S., Williams C., Sheppard H.W., Hanson C.V., Zolla-Pazner S. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the HIV-1 envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:3238-3242.
12. Gorny M.K., Xu J.-Y., Karwowska S., Buchbinder A., Zolla-Pazner S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 1993, 150(2):635-643.
13. Gorny M.K., Moore J.P., Conley A.J., Karwowska S., Sodroski J., Williams C., Burda S., Boots L.J., Zolla-Pazner S. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of HIV-1. J. Virol. 1994, 68:8312-8320.
14. Gorny M.K., VanCott T.C., Hioe C., Israel Z.R., Michael N.L., Conley A.J., Williams C., Kessler J.A., Chigurupati P., Burda S., Zolla-Pazner S. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J. Immunol. 1997, 159(10):5114-5122.
15. Gorny M.K., VanCott T.C., Williams C., Revesz K., Zolla-Pazner S. Effects of oligomerization on the epitopes of the Human Immunodeficiency Virus Type 1 envelope glycoproteins. Virology 2000, 267:220-228.
16. Gorny M.K., Williams C., Volsky B., Revesz K., Cohen S., Polonis V.R., Honnen W.J., Kayman S.C., Krachmarov C.P., Pinter A., Zolla-Pazner S. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize HIV-1 primary isolates from various clades. J. Virol. 2002, 76(18):9035-9045.
17. Gorny M.K., Wang X.H., Williams C., Volsky B., Revesz K., Witover B., Burda S., Urbanski M., Nyambi P., Krachmarov C., Pinter A., Zolla-Pazner S., Nadas A. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Mol. Immunol. 2009, 46(5):917-926.
18. Gorny M.K., Sampson J., Li H., Jiang X., Totrov M., Wang X.-H., Williams C., O'Neal T., Volsky B., Li L., Cardozo T., Nyambi P., Zolla-Pazner S., Kong X.-P. Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure. PLoS One 2011, 6(12):e27780.
19. He Y., Honnen W.J., Krachmarov C.P., Burkhart M., Kayman S.C., Corvalan J., Pinter A. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. J. Immunol. 2002, 169(1):595-605.
20. Hioe C.E., Wrin T., Seaman M.S., Yu X., Wood B., Self S., Williams C., Gorny M.K., Zolla-Pazner S. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS One 2010, 5(4):e10254.
21. Huang C.C., Venturi M., Majeed S., Moore M.J., Phogat S., Zhang M.Y., Dimitrov D.S., Hendrickson W.A., Robinson J., Sodroski J., Wyatt R., Choe H., Farzan M., Kwong P.D. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(9):2706-2711.
22. Huang C.C., Lam S.N., Acharya P., Tang M., Xiang S.H., Hussan S.S., Stanfield R.L., Robinson J., Sodroski J., Wilson I.A., Wyatt R., Bewley C.A., Kwong P.D. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007, 317(5846):1930-1934.
23. Israel Z.R., Gorny M.K., Palmer C., McKeating J.A., Zolla-Pazner S. Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1 infected individuals. AIDS 1997, 11(1):128-130.
24. Jiang X., Burke V., Totrov M., Williams C., Cardozo T., Gorny M.K., Zolla-Pazner S., Kong X.-P. Conserved structural elements in the V3 crown of HIV-1 GP120. Nat. Struct. Mol. Biol. 2010, 17(8):955-961.
25. Karasavvas N., Billings E., Rao M., Currier J., Michael N., Rerks-Ngarm S., Pitisuttithum P., Kaewkungwal J., Ngauy V., Nitayaphan S., Madnote S., Arworn D., Kim J., de Souza M. The Thai phase iii clinical trial (RV144) induces the generation of antibodies that target a conserved region within the V2 loop of gp120. AIDS Res. Hum. Retroviruses 2011, 27:A-29.
26. Kayman S.C., Wu Z., Revesz K., Chen H., Kopelman R., Pinter A. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J. Virol. 1994, 68(1):400-410.
27. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393(6686):648-659.
28. Li H., Pauza C.D. HIV envelope-mediated, CCR5/alpha4beta7-dependent killing of CD4-negative gammadelta T cells which are lost during progression to AIDS. Blood 2011, 118(22):5824-5831.
29. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., Montefiori D.C. Human Immunodeficiency Virus Type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005, 79(16):10108-10125.
30. Luftig M.A., Mattu M., Di Giovine P., Geleziunas R., Hrin R., Barbato G., Bianchi E., Miller M.D., Pessi A., Carfi A. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat. Struct. Mol. Biol. 2006, 13(8):740-747.
31. Marks J.D., Tristem M., Karpas A., Winter G. Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. Eur. J. Immunol. 1991, 21(4):985-991.
32. McKeating J.A., Shotton C., Cordell J., Graham S., Balfe P., Sullivan N., Charles M., Page M., Bolmstedt A., Olofsson S., Kayman S.C., Wu Z., Pinter A., Dean C., Sodroski J., Weiss R.A. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J. Virol. 1993, 67:4932-4944.
33. McKeating J.A., Shotton C., Jeffs S., Palmer C., Hammond A., Lewis J., Oliver K., May J., Balfe P. Immunogenicity of full length and truncated forms of the human immunodeficiency virus type I envelope glycoprotein. Immunol. Lett. 1996, 51:101-105.
34. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., O'Dell S., Patel N., Shahzad-ul-Hussan S., Yang Y., Zhang B., Zhou T., Zhu J., Boyington J.C., Chuang G.Y., Diwanji D., Georgiev I., Kwon Y.D., Lee D., Louder M.K., Moquin S., Schmidt S.D., Yang Z.Y., Bonsignori M., Crump J.A., Kapiga S.H., Sam N.E., Haynes B.F., Burton D.R., Koff W.C., Walker L.M., Phogat S., Wyatt R., Orwenyo J., Wang L.X., Arthos J., Bewley C.A., Mascola J.R., Nabel G.J., Schief W.R., Ward A.B., Wilson I.A., Kwong P.D. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480(7377):336-343.
35. Moseri A., Tantry S., Sagi Y., Arshava B., Naider F., Anglister J. An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120. Virology 2010, 401(2):293-304.
36. + T cells as key targets in mucosal transmission. PLoS Pathog. 2011, 7(2):e1001301.
37. Nyambi P.N., Gorny M.K., Bastiani L., van der Groen G., Williams C., Zolla-Pazner S. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J. Virol. 1998, 72(11):9384-9391.
38. Nyambi P.N., Mbah H.A., Burda S., Williams C., Gorny M.K., Nadas A., Zolla-Pazner S. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J. Virol. 2000, 74(15):7096-7107.
39. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276A:307-326.
40. Owens G.P., Winges K.M., Ritchie A.M., Edwards S., Burgoon M.P., Lehnhoff L., Nielsen K., Corboy J., Gilden D.H., Bennett J.L. VH4 gene segments dominate the intrathecal humoral immune response in multiple sclerosis. J. Immunol. 2007, 179(9):6343-6351.
41. Pinter A., Honnen W.J., Kayman S.C., Trochev O., Wu Z. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine 1998, 16(19):1803-1811.
42. Pinter A., Honnen W.J., He Y., Gorny M.K., Zolla-Pazner S., Kayman S.C. The V1/V2 domain of gp120 is a global regulator of sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J. Virol. 2004, 78(10):5205-5215.
43. Pinter A., Honnen W.J., D'Agostino P., Gorny M.K., Zolla-Pazner S., Kayman S.C. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type I primary isolates. J. Virol. 2005, 79(11):6909-6917.
44. Raman S., Vernon R., Thompson J., Tyka M., Sadreyev R., Pei J., Kim D., Kellogg E., DiMaio F., Lange O., Kinch L., Sheffler W., Kim B.H., Das R., Grishin N.V., Baker D. Structure prediction for CASP8 with all-atom refinement using Rosetta. Proteins 2009, 77(Suppl 9):89-99.
45. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361(23):2209-2220.
46. Rizzuto C.D., Wyatt R., Hernandez-Ramos N., Sun Y., Kwong P.D., Hendrickson W.A., Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998, 280(5371):1949-1953.
47. Sagar M., Wu X., Lee S., Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 2006, 80(19):9586-9598.
48. Scheid J.F., Mouquet H., Feldhahn N., Seaman M.S., Velinzon K., Pietzsch J., Ott R.G., Anthony R.M., Zebroski H., Hurley A., Phogat A., Chakrabarti B., Li Y., Connors M., Pereyra F., Walker B.D., Wardemann H., Ho D., Wyatt R.T., Mascola J.R., Ravetch J.V., Nussenzweig M.C. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458(7238):636-640.
49. Seaman M.S., Janes H., Hawkins N., Grandpre L.E., Devoy C., Giri A., Coffey R.T., Harris L., Wood B., Daniels M.G., Bhattacharya T., Lapedes A., Polonis V.R., McCutchan F.E., Gilbert P.B., Self S.G., Korber B.T., Montefiori D.C., Mascola J.R. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 2010, 84(3):1439-1452.
50. Shotton C., Arnold C., Sattentau Q., Sodroski J., McKeating J.A. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 1995, 69(1):222-230.
51. Spurrier B., Sampson J., Totrov M., Li H., O'Neal T., Williams C., Robinson J., Gorny M.K., Zolla-Pazner S., Kong X.-P. Structural analysis and computational modeling of human and macaque monoclonal antibodies provide a model for the quaternary neutralizing epitope of HIV-1 gp120. Structure (London, England: 1993) 2011, 19(5):691-699.
52. Tomaras G.D., Haynes B.F. Strategies for eliciting HIV-1 inhibitory antibodies. Curr. Opin. HIV AIDS 2010, 5(5):421-427.
53. Vagin A., Teplyakov A. A translation-function approach for heavy-atom location in macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 1998, 54(Pt 3):400-402.
54. van Gils M.J., Bunnik E.M., Boeser-Nunnink B.D., Burger J.A., Terlouw-Klein M., Verwer N., Schuitemaker H. Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies. J. Virol. 2011, 85(14):6986-6995.
55. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.A., Frey S.M., Hammond P.W., Miiro G., Serwanga J., Pozniak A., McPhee D., Manigart O., Mwananyanda L., Karita E., Inwoley A., Jaoko W., Dehovitz J., Bekker L.G., Pitisuttithum P., Paris R., Allen S., Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., Burton D.R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326(5950):285-289.
56. Warrier S.V., Pinter A., Honnen W.J., Girard M., Muchmore E., Tilley S.A. A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. J. Virol. 1994, 68(7):4636-4642.
57. White T.A., Bartesaghi A., Borgnia M.J., Meyerson J.R., de la Cruz M.J.V., Bess J.W., Nandwani R., Hoxie J.A., Lifson J.D., Milne J.L.S., Subramaniam S. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog. 2010, 6(12):e1001249.
58. Wu Z., Kayman S.C., Honnen W., Revesz K., Chen H., Vijh-Warrier S., Tilley S.A., McKeating J., Shotton C., Pinter A. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. J. Virol. 1995, 69(4):2271-2278.
59. Wu L., Gerard N.P., Wyatt R., Choe H., Parolin C., Ruffing N., Borsetti A., Cardoso A.A., Desjardin E., Newman W., Gerard C., Sodroski J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384(6605):179-183.
60. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., Longo N.S., McKee K., O'Dell S., Louder M.K., Wycuff D.L., Feng Y., Nason M., Doria-Rose N., Connors M., Kwong P.D., Roederer M., Wyatt R.T., Nabel G.J., Mascola J.R. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329(5993):856-861.
61. Wu S.-R., LAgving R., Lindqvist B., Hebert H., Koeck P.J.B., SjAgberg M., Garoff H. Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(44):18844-18849.
62. Zolla-Pazner S., Cardozo T. Structure-function relationships of HIV-1 envelope sequence-variable regions provide a paradigm for vaccine design. Nat. Rev. Immunol. 2010, 10(7):527-535.
63. Zolla-Pazner S., Kong X., Jiang X., Cardozo T., Nadas A., Cohen S., Totrov M., Seaman M.S., Wang S., Lu S. Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J. Virol. 2011, 85(19):9887-9898.
64. Zolla-Pazner S., Cardozo T., deCamp A., Haynes B., Kim J., Kong X., Michael N., Rerks-Ngarm S., Williams C. V2-reactive antibodies in RV144 vaccinees' plasma. AIDS Res. Hum. Retroviruses 2011, 27:A-21.